Special Issue "Feature Papers in Sinusitis 2022"

A special issue of Sinusitis (ISSN 2673-351X).

Deadline for manuscript submissions: closed (31 December 2022) | Viewed by 1729

Special Issue Editor

Allergy Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Largo F. Vito, 1, 00168 Rome, Italy
Interests: diagnosis and therapy of respiratory allergy; diagnosis and treatment of food allergies/intolerances; diagnosis and therapy of latex allergy; diagnosis and treatment of allergies/intolerances to drugs; diagnosis and treatment of insect venom allergy; diagnosis and treatment of nickel allergy; diagnosis and treatment of contact allergies; diagnosis and therapy of chronic urticaria; medical therapy of nasal polyps
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

We are pleased to announce a Special Issue entitled “Feature Paper in Sinusitis 2022”. Sinusitis is an international, peer-reviewed, open access journal, which provides an advanced forum for studies on all aspects of rhinology. The journal will join other successful international journals in the field of rhinology, with the aim of promoting knowledge and important new findings. Though this is a young, new journal, we expect it to experience rapid and exponential growth, as other new journals have achieved in the MDPI platform.

In this Special Issue, we are inviting manuscripts from all sinusitis fields considered to be of interest to our international readers. In this case, well-designed studies and good datasets are required to promote the quality of, and interest in, our new journal. We welcome both original research articles and comprehensive review papers. Papers in this Special Issue will be published via our open access platform after a thorough peer review, a process which will benefit both our authors and readers.

You are welcome to send short proposals for feature paper submissions to the Editorial Office (sinusitis@mdpi.com) before submission.

Dr. Eleonora Nucera
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Sinusitis is an international peer-reviewed open access semiannually journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • prevention, diagnosis, and management of rhinosinusitis Sinusitis causes
  • chronic and acute sinusitis
  • sinusitis related to tumors, smoking, cystic fibrosis, systemic diseases
  • sinusitis complications
  • pathophysiology and pathogenesis of sinusitis and asthma
  • epidemiological studies on rhinosinusitis and asthma
  • molecular genetics in sinusitis
  • pharmacology in sinusitis
  • clinical symptoms and therapeutics
  • new diagnostic tools and techniques
  • viral, fungal, and bacterial infections
  • veterinary sciences

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:


Immunomodulators Containing Epicor, Colostrum, Vitamin D, Zinc, Lactobacilli and Bifidobacterium Reduce Respiratory Exacerbations in Children and Adults with Chronic Pulmonary Diseases
Sinusitis 2022, 6(2), 66-76; https://doi.org/10.3390/sinusitis6020009 - 02 Dec 2022
Viewed by 1245
(1) Background: A number of studies have demonstrated the connection between developing or exacerbating chronic respiratory diseases in adults and children. However, still, few studies focus on reducing exacerbations via immunomodulation. (2) Methods: In this pilot study, a total of 25 pediatric and [...] Read more.
(1) Background: A number of studies have demonstrated the connection between developing or exacerbating chronic respiratory diseases in adults and children. However, still, few studies focus on reducing exacerbations via immunomodulation. (2) Methods: In this pilot study, a total of 25 pediatric and adult patients with bronchial asthma (BA) and chronic obstructive pulmonary disease (COPD)/persistent bacterial bronchitis (PBB) were included, administered over-the-counter (OTC) immunomodulators and followed up for 6 or 12 months. (3) Results: We observed a decrease in the frequency of exacerbations with slight improvements in functional respiratory indicators in adults on their second and third visits and a reduced number of exacerbations and improved spirometry indices in children with BA, although exacerbations requiring hospital admission remained at a similar rate. (4) Conclusions: We confirmed that the number of exacerbations of underlying chronic respiratory disease in adults and children could be reduced after the administration of OTC immunomodulators, probably by optimizing the immune resistance to common viral infections. Full article
(This article belongs to the Special Issue Feature Papers in Sinusitis 2022)
Show Figures

Figure 1

Back to TopTop